Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02636036 | Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors | PHASE1 | COMPLETED | 51 | — | — | Jan 25, 2016 | Oct 8, 2021 | Nov 9, 2021 | 6 | United States |
Review of adverse events including serious adverse events (SAEs), adverse events meeting protocol defined DLT criteria, adverse events leading to study treatment or study discontinuation, and adverse events resulting in death
Maximum tolerated dose (MTD) / maximum feasible dose (MFD) of enadenotucirev administered IV in combination with nivolumab.
| Arm | Type | Description |
|---|---|---|
| enadenotucirev and nivolumab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| enadenotucirev | BIOLOGICAL | - |
| nivolumab | BIOLOGICAL | - |
Inclusion Criteria: * Adult males or females aged 18 years or over * Disease status: - Diagnosis of metastatic or advanced CRC, UCC, SCCHN, salivary gland cancer or NSCLC not responding to standard therapy or for whom no standard treatment exists * For patients who have received prior PD-1 / PD-L1 ...